Expanded Access Programs: Opportunities and Challenges for Pharma

Expanded Access Programs: Opportunities and Challenges for Pharma

Code: FW-20150411 | Published: Apr-2015 | Pages: - | FirstWord
Price :
$595.00
USD

* Required Fields

$595.00

Details




Expanded access programmes make available investigational drugs to chronically sick or dying patients who have no other licenced product or clinical trial alternative. Driven by clinicians and patients, this highly-emotive area has both benefits and risks for pharma. What are the advantages? Where are the dangers? Does pharma have a moral imperative to engage?


Expanded Access Programs: Opportunities and Challenges for Pharma is a detailed report for industry management who must assess, approve or manage expanded access requests and programmes. Enriched with case studies, the report reveals the "real-world" experience and opinions of 17 senior industry, regulatory and stakeholder experts in the US and Europe and presents critical insights on the current operating environment for expanded access programmes.








Key Benefits

- Understand clinician and patient drivers for expanded access
- Formulate strategies to respond to requests that meet the needs of the wide variety of stakeholders involved
- Understand the complex and varying regulatory requirements in leading markets
- Balance the risks and "real-world" research benefits of engaging in expanded access programmes
- Assess whether running your own expanded access programmes or engaging a service company is the route to go
- Review the therapeutic areas currently attracting interest for expanded access programmes
- Be aware of the PR benefits and dangers of engaging in expanded access programmes
- Understand how "Right to Try" and CURE legislation may impact this area in the US



Answers to Critical Questions

- Expanded Access: how best to manage clinician/patient requests?
- Regulation of expanded access programmes varies widely in the US and EU - what are the essentials you need to know?
- Companies are often expected to foot the bill for expanded access programmes - so what are the research and communication upsides that would support your participation?
- What role can service companies play in smoothing access and management between pharma and clinicians/patients?
- Avoiding unintentional consequences: how could expanded access impact the main drive to get the compound to market for all patients?
- Media can be valuable partners in getting awareness of expanded access programme availability, but can also backfire if things dont go to plan. How can you manage communications and avoid falling into a PR black hole?


Top Takeaways

- Understand the factors that drive patients and clinicians to submit requests for early access to investigational drugs
Be aware of the positive - if complicated - regulatory environment in the US and EU governing early access programmes
- Examine the financial implications: you may get paid, but more often youll be footing the bill
- Learn from "real world" experience on how industry is engaging with expanded access programmes and meeting the challenges they present
- Identify the key benefits that accrue in terms of early exposure of your investigational drug in a real world setting
- Appreciate how an early access programme can help support and speed your product application, and also how they can slow progress to regulatory approval.


Expert Contributors


Pharma and biotech experts

- CEO and Founder, radiopharmaceutical company
- Chief Commercial Officer, global biopharmaceutical
- Senior Director of Global Pricing and Reimbursement, global biopharmaceutical
- CEO, biotechnology company
- A representative from a leading biotech company
- A representative from a top 15 pharma company
- CEO, pharma company
- COO, biopharmaceutical company
- Senior medical director, pharma company

Service provider experts

- Head of Project Management, Global Access Programmes
- Senior Vice President, Global Access Programmes
- Head, US programme operations
- Director, commercial development
- Marketing Director
- Senior Project Director

Patient advocacy groups

- President and co-founder, Marti Nelson Cancer Foundation
- President and founder, Melanoma International Foundation

Regulatory authorities

- Spokesperson, UKs Medicines and Healthcare Products Regulatory Agency




About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.



- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients